Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Shilpa's CDMO customer placed binding purchase order

Gavi outlines plans to support access to new vaccines

The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia

Investing in Malaysia's largest clinic operator to expand the healthcare business

Ayush gets big boost in the North East

India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid

Briefs: Venus Remedies and Shivalik Rasayan

Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA